Did Cognition beat or miss consensus estimates last quarter?

What factors drove the changes in Cognition's revenue and profit?

What were the key takeaways from Cognition's earnings call?

What is the market's earnings forecast for Cognition next quarter?

What is the revenue and EPS growth rate for Cognition year over year?

What is Cognition's latest dividend and current dividend yield?

What is Cognition's gross profit margin?

What guidance did Cognition's management provide for the next earnings period?

- **DLB Psychosis Priority**: Zervimesine targeting unmet need in DLB psychosis with 86% symptom progression reduction in phase II, seeking FDA registrational path.
- **EAP Success**: Expanded access program demand highlights real-world impact on patient daily lives.
- **Financial Stability**: $37M cash runway through mid-2027, reduced expenses driving 31% net loss improvement.
- **Regulatory Momentum**: FDA meetings and EMA alignment to define global trial strategy for DLB psychosis.

**【CEO Summary Section】**
- Cognition Therapeutics is focused on developing zervimesine (CT-1812) for neurodegenerative diseases, with recent phase II studies in dementia with Lewy bodies (DLB) and Alzheimer's disease.
- Enrollment completed in the 545-patient START trial for early Alzheimer's disease, with top-line results expected in 2027.
- Expanded Access Program (EAP) for DLB psychosis has shown strong patient demand and positive anecdotal feedback, with funding for another 9-12 months.

**【CMO Commentary】**
- Phase II SHIMMER study showed zervimesine slowed DLB psychosis progression by 86% vs. placebo, targeting disease pathophysiology rather than acute symptoms.
- FDA meetings with the Division of Psychiatry suggest a potential registrational path for DLB psychosis, similar to approved treatments for Alzheimer's and Parkinson's dementia.
- Regulatory alignment with EMA and global trial planning are pending FDA feedback.

**【CFO Financial Commentary】**
- Cash position as of December 2025: $37 million (including $35.7 million in NIA grants), sufficient for operations through Q2 2027.
- 2025 R&D expenses: $37.2 million (down 11% from 2024), driven by completed trials.
- G&A expenses: $10.6 million (down 14% from 2024), due to reduced stock-based compensation.
- Net loss: $23.5 million (vs. $34 million in 2024), reflecting cost optimization.

**【Q&A Highlights】**
- No plans for ophthalmology partnerships; focus remains on DLB psychosis.
- DLB trial design will prioritize psychosis endpoints, with secondary measures for cognition and motor function.
- Tablet formulation and bioavailability studies expected to complete in 2026.
- Combination therapy data with acetylcholinesterase inhibitors and immunotherapies will be shared post-START trial results.

Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Transcript

- **Strategic Reprioritization**: Terminated dry AMD study to focus on AD/DLB, extending cash runway to Q4 2025.
- **FDA Milestones**: Upcoming End-of-Phase II meetings to lock in trial designs for AD and DLB.
- **Partnership Pursuit**: Actively seeking non-dilutive funding; potential for single-indication deals.
- **Clinical Differentiation**: Zervimesine shows broad efficacy in DLB without biomarker enrichment; AD trials may use tau cutoffs.
- **Manufacturing Readiness**: Novel chemical process filed for patents; CMO in place for commercial scale.


**【CEO Opening Remarks】**
- Focused on advancing zervimesine (CT1812) for Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), with Phase II data showing strong efficacy signals.
- Terminated Phase II dry AMD study to prioritize AD/DLB programs, extending cash runway into Q4 2025.
- Seeking FDA End-of-Phase II meetings for AD and DLB to finalize registrational trial designs.
- Exploring partnerships for non-dilutive funding and Phase III readiness, including novel manufacturing process and CMO agreements.

**【CFO Financial Update】**
- Cash and equivalents: $25M (Dec 31, 2024); NIA grant balance: $50M.
- 2024 R&D expenses: $41.7M (vs. $37.2M in 2023), driven by Phase II trial costs.
- Sold ~20M shares via ATM in 2024, raising $12.8M.
- Net loss: $34M (2024) vs. $25.8M (2023), driven by higher R&D spend.

**【Q&A Key Takeaways】**
1. **FDA Meeting Strategy**: 
   - Planning to propose enrichment biomarkers (e.g., tau cutoff) for AD trials, similar to SHINE study.
   - DLB trials may not require biomarker enrichment due to broad efficacy across subgroups.
   - Targeting doses below 300mg to balance efficacy and safety.
2. **Partnership Outlook**: 
   - Actively engaging with biopharma partners for co-development or funding; no deal announced yet.
   - Potential interest in single indication (e.g., DLB) vs. both AD and DLB.
3. **Competitive Landscape**: 
   - No approved therapies for DLB; zervimesine's neuropsychiatric symptom focus aligns with unmet need.
   - Europe not expected to offer accelerated approval; pursuing traditional Phase III pathways.
   - NIH funding uncertain for Phase III, relying on partnerships and capital markets.


Actual	-0.415	-0.17	-0.25	-0.29	-0.2	-0.21	-0.16	-0.22	-0.27	-0.27	-0.18	-0.25	-0.1887	-0.14	-0.11	-0.01
Forecast	-0.26	-0.2867	-0.31	-0.3833	-0.225	-0.1767	-0.1773	-0.2371	-0.32	-0.2465	-0.2357	-0.1967	-0.17	-0.116	-0.105	-0.0775
Surprise	-59.62%	+40.70%	+19.35%	+24.34%	+11.11%	-18.85%	+9.76%	+7.21%	+15.63%	-9.53%	+23.63%	-27.10%	-11.00%	-20.69%	-4.76%	+87.10%

Actual	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

CGTX

CGTX fundamentals

CGTX Q4 2025 Earnings

Earnings Call

You can ask Aime

CGTX

CGTX fundamentals

CGTX Q4 2025 Earnings

Earnings Call

CGTX Earnings Call Summary for Q4/2025Today8:30 AM on Mar 26, 2026

CGTX Earnings Call Summary for Q2/2025 Mar 26, 2026

CGTX Earnings Call Summary for Q1/20257:00 AM on May 6, 2025

CGTX Earnings Call Summary for Q4/20248:00 AM on Mar 20, 2025

CGTX Earnings Call Summary for Q3/2024 Mar 26, 2026

You can ask Aime